瑕疵情人参考文献
[1]
Berni CananiR, TerrinG, Borrelli, et al、Short-and long-term therapeutic efficacy of nutrition theray and corticosteroids in paediatric Crohn′s disease [J]、Dig Liver Dis, 2006, 38: 381–387、[2]
CaprilliR, GassullMA, EscherJC, et al、European evidence based consensus on the diagnosis and management of Crohn′s disease:special situation [J]、Gut, 2006, 55 (Suppl 1):i36–i58、
[3]
OtleyA, SteinhartAH、Budesonide for induction of remission in Crohn′s disease [J/OL]、Cochrane Database Syst Rev, 2005: CD000296、(2005-10-19)[2013-08-01]、、
[4]
LevineA, KoriM, DinariG, et al、parison of two dosing methods for induction of response and remission with oral budesonide in activepediatric Crohn′s disease:a randomized placebo-controlled trial [J]、Inflamm Bowel Dis, 2009, 15: 1055–1061、
[5]
PrefontaineE, SutherlandLR, MacdonaldJK, et al、Azathioprine or 6-mercaptoputine for maintance of remission in Crohn′s disease [J/OL]、Cochrane Database Syst Rev, 2009: CD000067、(2009-01-21)[2013-08-01]、、
[6]
PrefontaineE, MacdonaldJK, SutherlandLR、Azathioprine or 6-mercaptoputine for induction of remission in Crohn′s disease [J/OL]、Cochrane Database Syst Rev, 2010: CD000545、(2010-06-16)[2013-08-01]、、
[7]
MarkowitzJ, GrancherK, KohnN, et al、A multicenter trial of 6-mercaptoputine and prednisone in children with newly diagnosed Crohn′s disease [J]、Gastroenterology, 2000, 119: 895–902、
[8]
RielloL, TalbotecC, GarnierLH, et al、Tolerance and efficacy of azathioprine in pediatric Crohn′s disease [J]、Inflamm Bowel Dis, 2011, 17: 2138–2143、
[9]
黄瑛、儿童炎症性肠病得治疗现状与展望[J]、中华儿科杂志, 2011, 49: 270–272、
[10]
ParashetteKR, MakamRC, CuffariC、Infliximab therapy in pediatric Crohn′s disease:a review[J]、Clin Exp Gastroenterol, 2010, 3: 57–63、
[11]
LionettiP, BronziniF, SalvestriniC, et al、Response to infliximab is related to disease duration in paediatric crohn′s disease [J]、Aliment Pharmacol Ther, 2003, 18: 425–431、
[12]
BorrelliO, BasciettoC, ViolaF, et al、Infliximab heals intestinal inflammatory lesions and restores growth in children with crohn′s disease [J]、Dig Liver Dis, 2004, 36: 342–347、
[13]
de RidderL, BenningaMA, TaminiauJA, et al、Infliximab use in children and adolescents with inflammatory bowel disease [J]、J Pediatr Gastroenterol Nutr, 2007, 45: 3–4、
[14]
HyamsJ, CrandallW, KugathasanS, et al、Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn′s disease in children [J]、Gastroenterology, 2007, 132: 863–873、
[15]
HyamJS, LererT, GriffithsA, et al、Long-term oute of maintenance infliximab therapy in children with Crohn′s disease [J]、Inflamm Bowel Dis, 2009, 15: 816–822、
[16]
BaldassanoR, BraeggerCP, EscherJC, et al、Infliximab(REMICADE) therapy in the treatment of pediatric Crohn′s disease[J]、Am J Gastroenterol, 2003, 98: 833–838、
[17]
LamireauT, CezardJP, DabadieA, et al、Efficacy and tolerance of infliximab in children and adoescents with crohn′s disease [J]、Inflamm Bowel Dis, 2004, 10: 745–750、
[18]
WantyC, StephenneX, SokalE, et al、Long-term oute of infliximab therapy in pediatric Crohn disease [J]、Arch Pediatr, 2011, 18: 863–869、
[19]
CrombeV, SalleronJ, SavoyeG, et al、Long-term oute of treatment with infliximab in pediatric-onset Crohn′s disease:a population-based study [J]、Inflamm Bowel Dis, 2011, 17: 2144–2152、
[20]
DaW, ZhuJ, WangL, et al、Adalimumab for crohn′s disease after infliximab treatment failure:a systematic review[J]、Eur J Gastroenterol Hepatol, 2013, 25: 885–891、
[21]
HyamsJS, GriffithsA, MarkowitzJ, et al、Safety and efficacy of adalimumab for moderate to severe crohn′s disease in children[J]、Gastroenterology, 2012, 143: 365–374、
[22]
MosliMH, FeaganBG、Vedolizumab for Crohn′s disease[J]、Expert Opin Biol Ther, 2013, 13: 455–463、
[23]
王雳, 白爱群、炎症性肠病得生物治疗[J]、世界华人消化杂志, 2010, 18: 107–112、[24]
FelipezLM, GokhaleR, TierneyMP, et al、Thalidomide use and outes in pediatric patients with Crohn disease refractory to infliximab and adalimumab [J]、J Pediatr Gastroenterol Nutr, 2012, 54: 28–33、
[25]
BanerjeeK, Camacho-HubnerC, BabinskaK, et al、Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn′s diseases [J]、J Pediatr Gastroenterol Nutr, 2004, 38: 270–275、
[26]
BuchananE, GauntW, CardiganT, et al、The use of exclusive enteral nutrition for induction of remission in children with Crohn′s disease demonstrates that disease phenotype dose not influence clinical remission [J]、Aliment Pharmacol Ther, 2009, 30: 501–507、
[27]
WerkstetterKJ, SchatzSB, AlbererM, et al、Influence of exclusive enteral nutrition therapy on bone dendity and geometry in newly diagnosed pediatric Crohn′s disease patients [J]、Ann Nutr Metab, 2013, 63: 10–16、
